Relationship Between Metabolic Toxicity and Efficacy of Everolimus in Patients With Neuroendocrine Tumors (NETs): A Pooled Analysis From the Randomized, Phase 3 RADIANT-3, and RADIANT-4 Trials
Fazio N, Carnaghi C, Valle JW, Herbst F, Ridolfi A, Strosberg J, Kulke MH, Pavel ME, Yao JC (2019)
Publication Type: Conference contribution
Publication year: 2019
Journal
Book Volume: 48
Pages Range: 433-433
Journal Issue: 3
Authors with CRIS profile
Involved external institutions
H. Lee Moffitt Cancer Center & Research Institute
United States (USA) (US)
University of Texas MD Anderson Cancer Center
United States (USA) (US)
University of Manchester
United Kingdom (GB)
Novartis Pharma S.A.S.
France (FR)
European Institute of Oncology / Istituto Europeo di Oncologia (IEO)
Italy (IT)
Boston Medical Center (BMC)
United States (USA) (US)
Novartis AG
Switzerland (CH)
Zentralkrankenhaus Bozen
Italy (IT)
United States (USA) (US)
University of Texas MD Anderson Cancer Center
United States (USA) (US)
University of Manchester
United Kingdom (GB)
Novartis Pharma S.A.S.
France (FR)
European Institute of Oncology / Istituto Europeo di Oncologia (IEO)
Italy (IT)
Boston Medical Center (BMC)
United States (USA) (US)
Novartis AG
Switzerland (CH)
Zentralkrankenhaus Bozen
Italy (IT)
How to cite
APA:
Fazio, N., Carnaghi, C., Valle, J.W., Herbst, F., Ridolfi, A., Strosberg, J.,... Yao, J.C. (2019). Relationship Between Metabolic Toxicity and Efficacy of Everolimus in Patients With Neuroendocrine Tumors (NETs): A Pooled Analysis From the Randomized, Phase 3 RADIANT-3, and RADIANT-4 Trials. (pp. 433-433).
MLA:
Fazio, Nicola, et al. "Relationship Between Metabolic Toxicity and Efficacy of Everolimus in Patients With Neuroendocrine Tumors (NETs): A Pooled Analysis From the Randomized, Phase 3 RADIANT-3, and RADIANT-4 Trials." 2019. 433-433.
BibTeX: Download